Pharmacodynamic effects of bezafibrate and niacin combination: Implications of the mode of administration

Journal of Pharmaceutical Sciences

Volumn 89, Issue 8, 2000, Pages 1046-1053

  Lomnicky, Yossef ^a   Haimov, Tali ^a   Luria, Myron H ^b   Friedman, Michael ^a   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Bezafibrate; Drug combination; Niacin; Pharmacodynamics; Sustained release

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; HYPERLIPIDEMIA; MALE; NONHUMAN; OSMOTIC PUMP; RAT; SLOW RELEASE FORMULATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033817674     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6017(200008)89:8<1046::AID-JPS9>3.0.CO;2-1     Document Type: Article

References (18)

1. Drugs used in the treatment of hyperlipoproteinemias
2. Pharmacodynamic aspects of sustained release formulations
3. Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: Pharmacodynamic rationale for sustained release preparation of the drug
4. The effect of mode of administration on the hypolipidemic activity of niacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidemic rats
5. Influence of nicotinic acid on the serum cholesterol in man
6. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio
7. Effects of drugs on clinical chemistry tests
8. Bezafibrate: An update of its pharmacology and use in the management of dyslipidaemia
9. +2 precipitation procedure for quantitation of high-density lipoprotein cholesterol
10. Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: Preliminary experience
11. Effect of bezafibrate and nicotinic acid on triton induced hyperlipidemia in CFY rats
12. Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in triton WR-1339 induced hyperlipidemia
13. Effects of the lipase inhibitors, triton WR-1339 and tetrahydrolipstatin on the synthesis and secretion of lipids by rat hepatocytes
14. Effects of triton WR-1339 and heparin on the transfer of surface lipids from triglyceride-rich emulsions to high density lipoproteins in rats
15. Hypolipidemic effects of intravenous pluronic L-81 fasted rats treated with triton WR-1339: Possible inhibition of hepatic lipoprotein secretion
16. Triton-induced hyperlipidemia in rats animal model for screening hypolipidemic drugs
17. Role of dosage regimen in controlling indirect pharmacodynamic responses